5.150USD-2.09%Mkt Cap: 243.19M USDP/E: —Last update: 2026-05-26
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candi…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap243.19M USD
Enterprise Value233.82M USD
Revenue (TTM)—
Gross Profit-9.65M USD
Net Income (TTM)-293.42M USD
Revenue/Share—
Last Price5.150 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees7
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS6033802058
Valuation
P/E (Trailing)—
P/E (Forward)-11.04
PEG—
EV/EBITDA-8.39
EV/Revenue—
P/S—
P/B-1.63
EPS (TTM)-37.03
EPS (Forward)-0.48
52W Range
1.35034% of range12.46
52W High12.46 USD
52W Low1.350 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE208.47%
ROA-299.51%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-13.51M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-2.28%
Net Debt-18.06M USD
Net Debt/EBITDA0.65
Balance Sheet
Debt/Equity—
Current Ratio17.65
Quick Ratio17.42
Book Value/Sh-3.2520 USD
Cash/Share1.676 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:8
Split DateJun 21, 2022
Analyst Consensus
Rating2.7 (Hold)
Target (Mean)9.500 USD
Target Range7.000 USD – 14.00 USD
# Analysts3
Ownership
Shares Out.46.59M
Float30.87M
Insiders3.34%
Institutions89.53%
Short Interest
Short Ratio6.8d
Short % Float2.99%
Short % Out.2.85%
Shares Short1.33M
Short (prev mo.)1.02M
Technical
SMA 506.215 (-17.1%)
SMA 2004.424 (+16.4%)
Beta-0.10
S&P 52W Chg28.31%
Avg Vol (30d)160.00K
Avg Vol (10d)179.29K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—